Back to News
Market Impact: 0.4
InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
InventisBio said its selective TYK2 inhibitor nomelcitinib (D-2570) met both the primary and key secondary endpoints in a registrational Phase III trial. The announcement concerns treatment of moderate-to-severe disease, but the supplied article text cuts off before specifying the condition or reporting numerical trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Automating Financial Model Updates: A Source-Controlled Workflow
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements